Early work by several groups reported co-administration of mAb with the vasculature promoting agents: angiotensin II, tumor necrosis factor-alpha, interferon, and interleukin 2 led to between 40% and 200% increases in mAb tumor uptake41–44. This evidence concerns the gene IL2 and neoplasm.